Represents the potential fee receivable for each license exercised under the collaborative agreement.

No definition available.

Name:	imgn_CollaborativeArrangementExerciseFeePotentialPerLicense
Namespace Prefix:	imgn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the amount of potential payments that could be received under the collaborative agreement.

+ References

No definition available.

+ Details

Name:	imgn_CollaborativeArrangementMilestonePaymentsPotential
Namespace Prefix:	imgn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Revenue from multiple-deliverable arrangements that include milestone and licensing fees revenue. Milestone revenue is consideration received upon achieving contractual goals. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets.

+ References

No definition available.

+ Details

Name:	imgn_LicenseAndMilestoneFees
Namespace Prefix:	imgn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the number of single-target licenses the company has right to use.

+ References

No definition available.

+ Details

Name:	imgn_NumberOfSingleTargetLicenses
Namespace Prefix:	imgn_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Cash received from collaborators during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromCollaborators
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=imgn_EliLillyAndCompanyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=imgn_RightToTestMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	imgn_ExerciseFeePerLicenseAxis=imgn_NoExerciseFeeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	imgn_ExerciseFeePerLicenseAxis=imgn_ExerciseFeeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=imgn_DevelopmentAndCommercializationLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	imgn_TypeOfLicenseAxis=imgn_ExclusiveDevelopmentAndCommercializationLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	imgn_DevelopmentPhaseAxis=imgn_PhaseIClinicalTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	imgn_MilestonePaymentsCategoryAxis=imgn_DevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	imgn_DevelopmentPhaseAxis=imgn_PhaseIIClinicalTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	imgn_MilestonePaymentsCategoryAxis=imgn_RegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	imgn_MilestonePaymentsCategoryAxis=imgn_SalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative Agreements (Details) $ in Thousands	1 Months Ended		3 Months Ended
Collaborative Agreements (Details) $ in Thousands	Sep. 30, 2015 USD ($)	Dec. 31, 2011 USD ($) item	Sep. 30, 2015 USD ($) item	Sep. 30, 2014 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)
Collaborative Agreements disclosures
Amount of arrangement consideration included in license and milestone fees			$ 6,070	$ 6,234
Costs related to the research and development services			$ 35,132	$ 28,018
Lilly \| Right-to-test agreement
Collaborative Agreements disclosures
Payments received under collaboration agreement		$ 20,000
Number of development and commercialization licenses taken \| item		3
Lilly \| Right-to-test agreement \| No exercise fee
Collaborative Agreements disclosures
License exercise fee, per subsequent license		$ 0
Lilly \| Right-to-test agreement \| Exercise fee of $2 million
Collaborative Agreements disclosures
License exercise fee, per subsequent license		$ 2,000				$ 2,000
Lilly \| Development and Commercialization License \| Exclusive license
Collaborative Agreements disclosures
Number of development and commercialization licenses taken \| item			3
Lilly \| Development and Commercialization License \| No exercise fee
Collaborative Agreements disclosures
Number of development and commercialization licenses taken \| item			1
Lilly \| Development and Commercialization License \| No exercise fee \| Maximum
Collaborative Agreements disclosures
Potential milestone payments for each subsequent license					$ 200,500
Lilly \| Development and Commercialization License \| Exercise fee of $2 million
Collaborative Agreements disclosures
Number of development and commercialization licenses taken \| item		2	2
License exercise fee, per subsequent license					2,000
Lilly \| Development and Commercialization License \| Exercise fee of $2 million \| Maximum
Collaborative Agreements disclosures
Potential milestone payments for each subsequent license					199,000
Lilly \| Development and Commercialization License \| Phase I clinical trial
Collaborative Agreements disclosures
Number of development and commercialization licenses taken \| item			2
Lilly \| Development and Commercialization License \| Development milestones \| No exercise fee
Collaborative Agreements disclosures
Potential milestone payments for each subsequent license					30,500
Lilly \| Development and Commercialization License \| Development milestones \| Exercise fee of $2 million
Collaborative Agreements disclosures
Potential milestone payments for each subsequent license					29,000
Lilly \| Development and Commercialization License \| Development milestones \| Phase I clinical trial
Collaborative Agreements disclosures
Payments received under collaboration agreement	$ 5,000
Potential milestone payments for each subsequent license	5,000		$ 5,000
Lilly \| Development and Commercialization License \| Development milestones \| Phase II clinical trial
Collaborative Agreements disclosures
Potential milestone payments for each subsequent license	$ 9,000		$ 9,000
Lilly \| Development and Commercialization License \| Regulatory milestones
Collaborative Agreements disclosures
Potential milestone payments for each subsequent license					70,000
Lilly \| Development and Commercialization License \| Sales milestones
Collaborative Agreements disclosures
Potential milestone payments for each subsequent license					$ 100,000